This is local prospective multicenter observational non-interventional local study. Primary study objective is investigate and describe prescription pattern of neurologists in secondary stroke or non-CNS (non-Central Nervous System) systemic embolism prevention in patients with AF (Atrial fibrillation) and prior stroke or TIA (Transient Ischemic attack) who treat with rivaroxaban at an initial visit and three follow-up visits.
- Rivaroxaban ( Xarelto, BAY59-7939) Other
Intervention Desc: Patients with prior stroke or TIA history and who have never taken anticoagulation treatment regarding AF before. One film-coated tablet contains Rivaroxaban 15 mg or 20mg ARM 1: Kind: Experimental Label: Group 1
- Observation: Cohort
- Perspective: Prospective
- Sampling: Non-Probability Sample
Male and female patients ≥ 18 years old with prior stroke or TIA history and who have never taken anticoagulation treatment regarding AF before and meet criteria of inclusion and exclusion.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Prescription pattern of neurologists in secondary stroke or non-CNS systemic embolism prevention in patients with AF and prior stroke or TIA who treat with rivaroxaban||up to 6 months||No|
|Secondary||Descriptive characteristics of patients after prior stroke/TIA in the need of secondary stroke prevention with Xarelto (gender, age, race, alcohol/smoking, BMI and BP abnormalities, CHA2DS2 VASC, HAS BLED, Rankin Score)||up to 6 months||No|
|Secondary||Identify time of start of anticoagulation therapy immediately after event (stroke or TIA) for secondary prevention in real life practice||up to 6 months||No|
|Secondary||Describe AE characteristics (frequency, severity, relation to treatment, AE treatment, AE outcome)||up to 6 months||Yes|
- Bayer Lead